These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 22253835)

  • 1. Prediction of glioblastoma multiform response to bevacizumab treatment using multi-parametric MRI.
    Najafi M; Soltanian-Zadeh H; Jafari-Khouzani K; Scarpace L; Mikkelsen T
    PLoS One; 2012; 7(1):e29945. PubMed ID: 22253835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.
    Artzi M; Bokstein F; Blumenthal DT; Aizenstein O; Liberman G; Corn BW; Ben Bashat D
    Eur J Radiol; 2014 Jul; 83(7):1250-1256. PubMed ID: 24809637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time course of imaging changes of GBM during extended bevacizumab treatment.
    Ananthnarayan S; Bahng J; Roring J; Nghiemphu P; Lai A; Cloughesy T; Pope WB
    J Neurooncol; 2008 Jul; 88(3):339-47. PubMed ID: 18389177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI assessment of relapsed glioblastoma during treatment with bevacizumab: volumetric measurement of enhanced and FLAIR lesions for evaluation of response and progression--a pilot study.
    Pichler J; Pachinger C; Pelz M; Kleiser R
    Eur J Radiol; 2013 May; 82(5):e240-5. PubMed ID: 23399039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab.
    Thompson EM; Dosa E; Kraemer DF; Neuwelt EA
    J Neurooncol; 2011 Jun; 103(2):353-60. PubMed ID: 20848300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decrease in the apparent diffusion coefficient in peritumoral edema for the assessment of recurrent glioblastoma treated by bevacizumab.
    Takano S; Kimu H; Tsuda K; Osuka S; Nakai K; Yamamoto T; Ishikawa E; Akutsu H; Matsuda M; Matsumura A
    Acta Neurochir Suppl; 2013; 118():185-9. PubMed ID: 23564129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab.
    Ellingson BM; Cloughesy TF; Lai A; Nghiemphu PL; Lalezari S; Zaw T; Motevalibashinaeini K; Mischel PS; Pope WB
    J Neurooncol; 2012 Jan; 106(1):111-9. PubMed ID: 21706273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.
    Ellingson BM; Cloughesy TF; Lai A; Mischel PS; Nghiemphu PL; Lalezari S; Schmainda KM; Pope WB
    Neuro Oncol; 2011 Oct; 13(10):1151-61. PubMed ID: 21856685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab.
    Chang K; Zhang B; Guo X; Zong M; Rahman R; Sanchez D; Winder N; Reardon DA; Zhao B; Wen PY; Huang RY
    Neuro Oncol; 2016 Dec; 18(12):1680-1687. PubMed ID: 27257279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study.
    Hattingen E; Jurcoane A; Bähr O; Rieger J; Magerkurth J; Anti S; Steinbach JP; Pilatus U
    Neuro Oncol; 2011 Dec; 13(12):1349-63. PubMed ID: 21890539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
    Schaub C; Greschus S; Seifert M; Waha A; Blasius E; Rasch K; Landwehr C; Mack F; Schäfer N; Stuplich M; Kebir S; Vilz B; Scheffler B; Boström J; Simon M; Urbach H; Glas M; Herrlinger U
    Oncology; 2013; 85(3):191-5. PubMed ID: 24008924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GPU-accelerated nonparametric kinetic analysis of DCE-MRI data from glioblastoma patients treated with bevacizumab.
    Hsu YH; Ferl GZ; Ng CM
    Magn Reson Imaging; 2013 May; 31(4):618-23. PubMed ID: 23200680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice.
    de Groot JF; Fuller G; Kumar AJ; Piao Y; Eterovic K; Ji Y; Conrad CA
    Neuro Oncol; 2010 Mar; 12(3):233-42. PubMed ID: 20167811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
    Wen Q; Jalilian L; Lupo JM; Molinaro AM; Chang SM; Clarke J; Prados M; Nelson SJ
    J Neurooncol; 2015 Jan; 121(2):331-9. PubMed ID: 25351579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
    Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
    Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma.
    LaViolette PS; Cohen AD; Prah MA; Rand SD; Connelly J; Malkin MG; Mueller WM; Schmainda KM
    Neuro Oncol; 2013 Apr; 15(4):442-50. PubMed ID: 23382287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classification of tumor area using combined DCE and DSC MRI in patients with glioblastoma.
    Artzi M; Blumenthal DT; Bokstein F; Nadav G; Liberman G; Aizenstein O; Ben Bashat D
    J Neurooncol; 2015 Jan; 121(2):349-57. PubMed ID: 25370705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.
    Kickingereder P; Brugnara G; Hansen MB; Nowosielski M; Pflüger I; Schell M; Isensee F; Foltyn M; Neuberger U; Kessler T; Sahm F; Wick A; Heiland S; Weller M; Platten M; von Deimling A; Maier-Hein KH; Østergaard L; van den Bent MJ; Gorlia T; Wick W; Bendszus M
    Radiology; 2020 Oct; 297(1):164-175. PubMed ID: 32720870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma.
    Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Ozcelik M; Esenkaya A; Saygi HM; Uzunoglu S; Cicin I
    Med Oncol; 2015 Feb; 32(2):460. PubMed ID: 25572814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab.
    Ellingson BM; Cloughesy TF; Lai A; Nghiemphu PL; Pope WB
    J Neurooncol; 2011 Oct; 105(1):91-101. PubMed ID: 21442275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.